BACE1 Function and Inhibition: Implications of Intervention in the Amyloid Pathway of Alzheimer’s Disease Pathology
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is a fatal progressive neurodegenerative disorder characterized by increasing loss in memory, cognition, and function of daily living. Among the many pathologic events observed in the progression of AD, changes in amyloid β peptide (Aβ) metabolism proceed fastest, and precede clinical symptoms. BACE1 (β-secretase 1) catalyzes the initial cleavage of the amyloid precursor protein to generate Aβ. Therefore inhibition of BACE1 activity could block one of the earliest pathologic events in AD. However, therapeutic BACE1 inhibition to block Aβ production may need to be balanced with possible effects that might result from diminished physiologic functions BACE1, in particular processing of substrates involved in neuronal function of the brain and periphery. Potentials for beneficial or consequential effects resulting from pharmacologic inhibition of BACE1 are reviewed in context of ongoing clinical trials testing the effect of BACE1 candidate inhibitor drugs in AD populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · cited 6×
“However, in a model of therapy in early AD or prevention of AD, slowing of accumulation seems to be more relevant than rapid clearance, where amyloid is in early stages of formation and accumulation is incomplete [4,6].”
BackgroundInfluentialSoluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744 · cited 1×
“Aβ in various forms including soluble oligomers [114,115] disrupt synaptic transmission and cognition, induce neurotoxicity, and contribute to the overall disease process [7,16,115,116].”
BackgroundJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Principles of early drug discovery
Hughes, J., Rees, S., Kalindjian, S., & Philpott, K. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01127.x · Cited by 2,859
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078 · cited 3×
“Increased level of amyloid is implicated as an early factor in AD [4], through increased production [116] or reduced clearance [117], with a resulting imbalance in the production and consumption “Aβ economy” [13].”
BackgroundAβ Oligomers – a decade of discovery
Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938 · cited 1×
“Aβ in various forms including soluble oligomers [114,115] disrupt synaptic transmission and cognition, induce neurotoxicity, and contribute to the overall disease process [7,16,115,116].”
BackgroundA mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738 · cited 17×
“The activity the aminopeptidase activity that generates Aβ3-x substrates for glutaminyl cyclase might be impacted by the Ala to Thr change in the P1 position of A673T-generated Aβ.”
BackgroundInfluentialAPP Processing and Synaptic Function
Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia, S., & Malinow, R. (2003) · Neuron · doi:10.1016/s0896-6273(03)00124-7 · Cited by 1,644 · cited 1×
“Alternatively, Aβ may function beneficially in synaptic transmission [9,10], synaptic feedback inhibition [11,12], and even as an anti-microbial peptide [118,119].”
Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity
Yan, R., Bienkowski, M. J., Shuck, M. E., Miao, H., Tory, M. C., Pauley, A. M., Brashler, J. R., Stratman, N. C., Mathews, W. R., Buhl, A. E., et al. (1999) · Nature · doi:10.1038/990107 · Cited by 1,438
The Alzheimer's Disease-Associated Amyloid β-Protein Is an Antimicrobial Peptide
Soscia, S. J., Kirby, J. E., Washicosky, K. J., Tucker, S. M., Ingelsson, M., Hyman, B., Burton, M. A., Goldstein, L. E., Duong, S., Tanzi, R. E., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009505 · Cited by 1,060
Neurotoxicity of Amyloid -Protein: Synaptic and Network Dysfunction
Mucke, L., & Selkoe, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006338 · Cited by 1,000 · cited 2×
“Aβ in various forms including soluble oligomers [114,115] disrupt synaptic transmission and cognition, induce neurotoxicity, and contribute to the overall disease process [7,16,115,116].”
BackgroundKumar, D. K. V., Choi, S. H., Washicosky, K. J., Eimer, W. A., Tucker, S., Ghofrani, J., Lefkowitz, A., McColl, G., Goldstein, L. E., Tanzi, R. E., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf1059 · Cited by 971
De Felice, F. G., Velasco, P. T., Lambert, M. P., Viola, K., Fernandez, S. J., Ferreira, S. T., & Klein, W. L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607483200 · Cited by 882
Jin, M., Shepardson, N., Yang, T., Chen, G., Walsh, D., & Selkoe, D. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017033108 · Cited by 876
Control of Peripheral Nerve Myelination by the ß-Secretase BACE1
Willem, M., Garratt, A. N., Novak, B., Citron, M., Kaufmann, S., Rittger, A., DeStrooper, B., Saftig, P., Birchmeier, C., & Haass, C. (2006) · Science · doi:10.1126/science.1132341 · Cited by 703 · cited 3×
“Neurogenesis, Astrogenesis 100% [170] Growth cone collapse 100% 3 [171] Axonal growth 100% 50–100% 4 [172–174] Spine density 60% 5 100% [175,176] Muscle Spindle 68% 6 100% [97] Myelination 100% 7 [77,78,88] Synaptic dysfunction 50% 5 100% 7 [176–179] Retinopathy 100% [180] Muscle coordination 100% [171,178,181] Memory…”
BackgroundBace1 modulates myelination in the central and peripheral nervous system
Hu, X., Hicks, C. W., He, W., Wong, P., Macklin, W. B., Trapp, B. D., & Yan, R. (2006) · Nature Neuroscience · doi:10.1038/nn1797 · Cited by 608 · cited 3×
“Neurogenesis, Astrogenesis 100% [170] Growth cone collapse 100% 3 [171] Axonal growth 100% 50–100% 4 [172–174] Spine density 60% 5 100% [175,176] Muscle Spindle 68% 6 100% [97] Myelination 100% 7 [77,78,88] Synaptic dysfunction 50% 5 100% 7 [176–179] Retinopathy 100% [180] Muscle coordination 100% [171,178,181] Memory…”
BackgroundHypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression
Sun, X., He, G., Qing, H., Zhou, W., Dobie, F., Cai, F., Staufenbiel, M., Huang, L. E., & Song, W. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606298103 · Cited by 605
Saido, T. C., Iwatsubo, T., Mann, D. M. A., Shimada, H., Ihara, Y., & Kawashima, S. (1995) · Neuron · doi:10.1016/0896-6273(95)90301-1 · Cited by 587 · cited 2×
“Additionally, production of pyrGluAβ species might be reduced if the amino acid change at position 2 in Aβ impedes the generation of Aβ3-x substrates for glutaminyl cyclase [110,111], reducing the impact of this highly aggregation prone Aβ species [112,113].”
The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective
Shaftel, S. S., Griffin, W. S. T., & O'Banion, M. K. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-7 · Cited by 565
Increased expression of the amyloid precursor β‐secretase in Alzheimer's disease
Holsinger, R. M. D., McLean, C. A., Beyreuther, K., Masters, C. L., & Evin, G. (2002) · Annals of Neurology · doi:10.1002/ana.10208 · Cited by 562
Reiman, E. M., Quiroz, Y. T., Fleisher, A. S., Chen, K., Velez-Pardo, C., Jimenez-Del-Rio, M., Fagan, A. M., Shah, A. R., Alvarez, S., Arbelaez, A., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70228-4 · Cited by 541 · cited 1×
“Accumulation of Aβ is one of the earliest events in the disease process, occurring to near completion 10–20 years prior to the onset of memory loss and other clinical symptoms [5].”
BackgroundMechanisms of Aβ Clearance and Degradation by Glial Cells
Ries, M., & Sastre, M. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00160 · Cited by 527 · cited 1×
“Extant Aβ is not reduced by BACE1 inhibition, and therefore reduction of Aβ is achieved by innate clearance mechanisms, including phagocytosis [156], transport proteins [156,157], and a growing list of candidate proteases that act upon soluble and insoluble forms of amyloid [158].”
BackgroundLaird, F. M., Cai, H., Savonenko, A. V., Farah, M. H., He, K., Melnikova, T., Wen, H., Chiang, H.-C., Xu, G., Koliatsos, V. E., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2766-05.2005 · Cited by 521
Zhang, X., Zhou, K., Wang, R., Cui, J., Lipton, S. A., Liao, F.-F., Xu, H., & Zhang, Y.-W. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608856200 · Cited by 436
Maturation and Endosomal Targeting of β-Site Amyloid Precursor Protein-cleaving Enzyme
Huse, J. T., Pijak, D. S., Leslie, G. J., Lee, V. M.-Y., & Doms, R. W. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004175200 · Cited by 402
Ferreira, S. T., Lourenco, M. V., Oliveira, M. M., & De Felice, F. G. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00191 · Cited by 373
Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer's disease–like pathology
Schilling, S., Zeitschel, U., Hoffmann, T., Heiser, U., Francke, M., Kehlen, A., Holzer, M., Hutter-Paier, B., Prokesch, M., Windisch, M., et al. (2008) · Nature Medicine · doi:10.1038/nm.1872 · Cited by 357
Amyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer’s Disease
Baranello, R., Bharani, K., Padmaraju, V., Chopra, N., Lahiri, D., Greig, N., Pappolla, M., & Sambamurti, K. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666141218140953 · Cited by 331 · cited 1×
“Extant Aβ is not reduced by BACE1 inhibition, and therefore reduction of Aβ is achieved by innate clearance mechanisms, including phagocytosis [156], transport proteins [156,157], and a growing list of candidate proteases that act upon soluble and insoluble forms of amyloid [158].”
BackgroundBenjannet, S., Elagoz, A., Wickham, L., Mamarbachi, M., Munzer, J. S., Basak, A., Lazure, C., Cromlish, J. A., Sisodia, S., Checler, F., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009899200 · Cited by 301
Savonenko, A. V., Melnikova, T., Laird, F. M., Stewart, K.-A., Price, D. L., & Wong, P. C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710373105 · Cited by 290
Physiological roles for amyloid β peptides
Pearson, H. A., & Peers, C. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2006.111203 · Cited by 286
The Low Density Lipoprotein Receptor-related Protein (LRP) Is a Novel β-Secretase (BACE1) Substrate
von Arnim, C. A. F., Kinoshita, A., Peltan, I. D., Tangredi, M. M., Herl, L., Lee, B. M., Spoelgen, R., Hshieh, T. T., Ranganathan, S., Battey, F. D., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414248200 · Cited by 258
Gowing, E., Roher, A. E., Woods, A. S., Cotter, R. J., Chaney, M., Little, S. P., & Ball, M. J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)78080-6 · Cited by 223
Crystal Structure of an Active Form of BACE1, an Enzyme Responsible for Amyloid β Protein Production
Shimizu, H., Tosaki, A., Kaneko, K., Hisano, T., Sakurai, T., & Nukina, N. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.02185-07 · Cited by 205
BACE1 Deficiency Causes Altered Neuronal Activity and Neurodegeneration
Hu, X., Zhou, X., He, W., Yang, J., Xiong, W., Wong, P., Wilson, C. G., & Yan, R. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.1334-10.2010 · Cited by 162 · cited 2×
“Neurogenesis, Astrogenesis 100% [170] Growth cone collapse 100% 3 [171] Axonal growth 100% 50–100% 4 [172–174] Spine density 60% 5 100% [175,176] Muscle Spindle 68% 6 100% [97] Myelination 100% 7 [77,78,88] Synaptic dysfunction 50% 5 100% 7 [176–179] Retinopathy 100% [180] Muscle coordination 100% [171,178,181] Memory…”
BackgroundVetrivel, K. S., Meckler, X., Chen, Y., Nguyen, P. D., Seidah, N. G., Vassar, R., Wong, P. C., Fukata, M., Kounnas, M. Z., & Thinakaran, G. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808920200 · Cited by 153 · cited 1×
“Propeptide 22–45 Folding, enhancement of activity [34–36] Disulfide bonds 216–420, 278–443, 330–380 Structural stability [30] Glycosylation 153, 172, 223, 354 Lysosomal targeting, degradation [37–39] Phosphorylation 498 Endosomal-lysosomal trafficking [40] Ubuiquitination 501 Trafficking, degradation [41,42] S-Palmito…”
BackgroundHarrison, S. M., Harper, A. J., Hawkins, J., Duddy, G., Grau, E., Pugh, P. L., Winter, P. H., Shilliam, C. S., Hughes, Z. A., Dawson, L. A., et al. (2003) · Molecular and Cellular Neuroscience · doi:10.1016/s1044-7431(03)00227-6 · Cited by 152
BACE overexpression alters the subcellular processing of APP and inhibits Aβ deposition in vivo
Lee, E. B., Zhang, B., Liu, K., Greenbaum, E. A., Doms, R. W., Trojanowski, J. Q., & Lee, V. M.-Y. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200407070 · Cited by 140
Two phases of disulfide bond formation have differing requirements for oxygen
Koritzinsky, M., Levitin, F., van den Beucken, T., Rumantir, R. A., Harding, N. J., Chu, K. C., Boutros, P. C., Braakman, I., & Wouters, B. G. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201307185 · Cited by 136 · cited 1×
“Interestingly, disulfide bond formation may be impaired in hypoxic conditions [51].”
BackgroundCai, J., Qi, X., Kociok, N., Skosyrski, S., Emilio, A., Ruan, Q., Han, S., Liu, L., Chen, Z., Bowes Rickman, C., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201101084 · Cited by 136 · cited 1×
“Neurogenesis, Astrogenesis 100% [170] Growth cone collapse 100% 3 [171] Axonal growth 100% 50–100% 4 [172–174] Spine density 60% 5 100% [175,176] Muscle Spindle 68% 6 100% [97] Myelination 100% 7 [77,78,88] Synaptic dysfunction 50% 5 100% 7 [176–179] Retinopathy 100% [180] Muscle coordination 100% [171,178,181] Memory…”
Yuan, J., Venkatraman, S., Zheng, Y., McKeever, B. M., Dillard, L. W., & Singh, S. B. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301659n · Cited by 135
Alzheimer’s disease as oligomeropathy
Ono, K. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2017.08.010 · Cited by 129 · cited 1×
“Myriad Aβ peptides have a varied propensity to oligomerize and aggregate with other Aβ peptides and assemblies thereof, with diverse effects on cognitoxicity and neurotoxicity [1,7,8].”
BackgroundPigoni, M., Wanngren, J., Kuhn, P.-H., Munro, K. M., Gunnersen, J. M., Takeshima, H., Feederle, R., Voytyuk, I., De Strooper, B., Levasseur, M. D., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0134-z · Cited by 125 · cited 1×
“Directly related to seizure phenotype observed in mice deficient in BACE1, Sez6 and Sez6L were identified [81] and validated [84] as BACE1 substrates, with Sez6 being implicated in susceptibility for febrile seizures [96].”
BackgroundKo, M. H., & Puglielli, L. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m804901200 · Cited by 111 · cited 1×
“Propeptide 22–45 Folding, enhancement of activity [34–36] Disulfide bonds 216–420, 278–443, 330–380 Structural stability [30] Glycosylation 153, 172, 223, 354 Lysosomal targeting, degradation [37–39] Phosphorylation 498 Endosomal-lysosomal trafficking [40] Ubuiquitination 501 Trafficking, degradation [41,42] S-Palmito…”
BackgroundUbiquitin Regulates GGA3-mediated Degradation of BACE1
Kang, E. L., Cameron, A. N., Piazza, F., Walker, K. R., & Tesco, G. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.092742 · Cited by 111 · cited 2×
“Recycling of BACE1 within endosomal compartments has been implicated in maintaining amyloidogenic activity [67,68], in opposition to lysosomal destination of BACE1 where it is degraded [42,69].”
BackgroundIdentification of Low Molecular Weight Pyroglutamate Aβ Oligomers in Alzheimer Disease
Wirths, O., Erck, C., Martens, H., Harmeier, A., Geumann, C., Jawhar, S., Kumar, S., Multhaup, G., Walter, J., Ingelsson, M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.178707 · Cited by 103
Hitt, B. D., Jaramillo, T. C., Chetkovich, D. M., & Vassar, R. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-31 · Cited by 99 · cited 2×
“Neurogenesis, Astrogenesis 100% [170] Growth cone collapse 100% 3 [171] Axonal growth 100% 50–100% 4 [172–174] Spine density 60% 5 100% [175,176] Muscle Spindle 68% 6 100% [97] Myelination 100% 7 [77,78,88] Synaptic dysfunction 50% 5 100% 7 [176–179] Retinopathy 100% [180] Muscle coordination 100% [171,178,181] Memory…”
BackgroundYe, X., Feng, T., Tammineni, P., Chang, Q., Jeong, Y. Y., Margolis, D. J., Cai, H., Kusnecov, A., & Cai, Q. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.2851-16.2017 · Cited by 70
Decreased plasma β‐amyloid in the Alzheimer's disease APP A 673 Tvariant carriers
Martiskainen, H., Herukka, S., Stančáková, A., Paananen, J., Soininen, H., Kuusisto, J., Laakso, M., & Hiltunen, M. (2017) · Annals of Neurology · doi:10.1002/ana.24969 · Cited by 64 · cited 3×
“Although production and inhibition of Aβ in plasma may not reflect that in the brain [106,189], the 28% reduction in plasma Aβ observed for A673T carriers [107] is aligned with the anticipated approximate 20% reduction in biochemical activity for Aβ production [15,104,105].”
BackgroundResultToh, W. H., & Gleeson, P. A. (2016) · Biochemical Journal · doi:10.1042/bcj20160147 · Cited by 62
Kang, E. L., Biscaro, B., Piazza, F., & Tesco, G. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.407072 · Cited by 55
Gadkar, K., Yadav, D. B., Zuchero, J. Y., Couch, J. A., Kanodia, J., Kenrick, M. K., Atwal, J. K., Dennis, M. S., Prabhu, S., Watts, R. J., et al. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.01.009 · Cited by 52
Cited by
Synaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic strategies
Chen, Y., Fu, A. K. Y., & Ip, N. Y. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.006 · Cited by 258
Lyu, Y., Meng, Z., Hu, Y., Jiang, B., Yang, J., Chen, Y., Zhou, J., Li, M., & Wang, H. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1394932 · Cited by 42
Is It the Twilight of BACE1 Inhibitors?
Hrabinova, M., Pejchal, J., Kucera, T., Jun, D., Schmidt, M., & Soukup, O. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200503023323 · Cited by 28
“As first mentioned by Koelsch [21] and as shown in the following table (Table 5), rather higher dose administration and target >50% reduction of Aβ was preferred in clinical studies.”
BackgroundVersatile nanomaterials for Alzheimer’s disease: Pathogenesis inspired disease-modifying therapy
Xi, Y., Chen, Y., Jin, Y., Han, G., Song, M., Song, T., Shi, Y., Tao, L., Huang, Z., Zhou, J., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.034 · Cited by 27
The Role of miR-128 in Neurodegenerative Diseases
Lanza, M., Cuzzocrea, S., Oddo, S., Esposito, E., & Casili, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076024 · Cited by 27
Metadata
- Authors
- Koelsch, G.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2017-10-13
- Volume
- 22
- Issue
- 10
- Pages
- 1723
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W2762071322
- Cited by
- 125
- References
- 53
- FWCI
- 7.04
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.